Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06369298 · ClinicalTrials.gov registry record · Phase 2

Study of JK07 in Patients With Chronic Heart Failure

A Phase 2 study of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction, sponsored by Salubris Biotherapeutics.

Recruiting
Registry status
Phase 2
Development phase
282
Enrollment target
20
Study locations

NCT06369298: Recruiting Phase 2 study of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction, sponsored by Salubris Biotherapeutics.

NCT06369298 is a Phase 2 study of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction that is actively recruiting participants, run by Salubris Biotherapeutics. The registered enrollment target is 282 participants, below the 2,282-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06369298, a Phase 2 study of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction, is actively recruiting participants, sponsored by Salubris Biotherapeutics.

RECRUITING
Registry status
Phase 2
Development phase
282 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of ≤ 40%. Cohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) \> 40% and ≤ 65%.

Primary Outcome

Incidence and severity of treatment emergent adverse events

Conditions Studied

Heart Failure With Preserved Ejection Fraction Heart Failure With Reduced Ejection Fraction

Interventions

  • DRUG Placebo
  • DRUG JK07

Study Locations (20)

California

  • Site 128 - Huntington Beach
  • Site 157 - Los Angeles
  • Site 158 - Orange
  • Site 116 - Pasadena
  • Site 129 - Santa Maria
  • Site 102 - Stanford
  • Site 113 - Torrance
  • Site 133 - Vista

Alabama

  • Site 121 - Alexander City
  • Site 130 - Birmingham
  • Site 139 - Birmingham
  • Site 138 - Huntsville

Florida

  • Site 161 - Coral Gables
  • Site 114 - Hialeah
  • Site 162 - Miami Lakes
  • Site 159 - Naples

Arizona

  • Site 111 - Phoenix

Arkansas

  • Site 127 - Little Rock

Georgia

  • Site 136 - Atlanta

Idaho

  • Site 143 - Boise

Trial Details

FieldValue
Enrollment Target 282 participants
Start Date 2024-03-28
Est. Completion 2026-06-30
Phase Phase 2
Salubris Biotherapeutics

3 total trials

What NCT06369298 shows while recruiting

NCT06369298 is an interventional study that assigns participants to a tested intervention. The registered 282 participants enrollment target is mid-sized for trials with a published cap, below the 2,282-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (88% lower).

The record links to 2 conditions, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06369298 names 20 study sites across 7 states, led by California, Alabama, Florida.

Frequently Asked Questions

What is clinical trial NCT06369298 about?

NCT06369298 is a clinical study titled "Study of JK07 in Patients With Chronic Heart Failure". This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with left ventricular ejecti...

What is the current status of trial NCT06369298?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 282 participants. The study started on 2024-03-28. Estimated completion is 2026-06-30.

What conditions does trial NCT06369298 study?

This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction.

What interventions are being tested in trial NCT06369298?

The interventions under investigation include: Placebo (DRUG), JK07 (DRUG).

Who is sponsoring clinical trial NCT06369298?

This trial is sponsored by Salubris Biotherapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06369298 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure With Preserved Ejection Fraction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06369298's enrollment target sits among peer trials

282 10th of 42 higher than 33 of 42 other Heart Failure With Preserved Ejection Fraction trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure With Preserved Ejection Fraction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02860364 · 282 participants · NA

    Comparing Hypothermic Temperatures During Hemiarch Surgery

  • NCT04867395 · 282 participants · NA

    A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity

  • NCT05101070 · 282 participants · Phase 1

    S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

  • NCT06276491 · 282 participants · Phase 1

    Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06369298

Source: ClinicalTrials.gov NCT06369298, the US trial registry maintained by the National Library of Medicine. NCT06369298 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.